Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

A girl with a solitary red bulla

Efficacy of the long-pulsed 1064-nm neodymium:yttrium-aluminum-garnet laser (LPND) (rejuvenation mode) in the treatment of papulopustular rosacea (PPR):

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Treatment of nevus depigmentosus using the 308-nm excimer laser: A retrospective study of 14 patients Jung Min Bae, MD, PhD, Han Mi Jung, MD, Hee Sun.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Assessing adherence with phototherapy protocols

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Characterization of disease burden, comorbidities, and treatment use in a large, US- based cohort: Results from the Corrona Psoriasis Registry Bruce Strober,

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Treatment of psoriasis vulgaris using low-dose naltrexone

SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss Elise A. Olsen, MD, Douglas Canfield, BS Journal.

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis Kristian Reich,

Lip edema Journal of the American Academy of Dermatology

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Mark D. Heibel, MD, Haley D. Heibel, MS JAAD Case Reports

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study.

Hugh Gloster, MD, Chesahna Kindred, MBA

Efficacy and safety of calcipotriol/betamethasone dipropionate ointment for the treatment of simple onycholysis: An open-label study Jung-Min Park, MD,

Medicaid acceptance among pediatric dermatologists

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Jennifer L. Hundley, MD, Christie L

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Etanercept therapy in two patients with psoriasis and concomitant hepatitis C Clara De Simone, MD, Andrea Paradisi, MD, Rodolfo Capizzi, MD, Angelo Carbone,

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Classification of facial psoriasis based on the distributions of facial lesions Seung Man Woo, MD, Jung Won Choi, MD, Hyun Sun Yoon, MD, Seong Jin Jo,

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot Chima, MD, Hee Jin Kim, MD, Jennifer Bares, MD, Christopher J. Yao, MPH, Giselle Singer, BS, Soo Jung Kim, MD, Jerry Bagel, MD, Mark Lebwohl, MD Journal of the American Academy of Dermatology Volume 81, Issue 3, Pages 857-859 (September 2019) DOI: 10.1016/j.jaad.2019.05.007 Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Week 16 results show the percentage of patients achieving Psoriasis Area and Severity Index (PASI)-100, PASI-90, PASI-75, and static Physician's Global Assessment (sPGA) scores of 0 or 1. AO, as observed; LOCF, last observation carried forward; NRI, nonresponder imputation. Journal of the American Academy of Dermatology 2019 81, 857-859DOI: (10.1016/j.jaad.2019.05.007) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions